Breaking News Instant updates and real-time market news.

TEVA

Teva

$19.02

0.07 (0.37%)

, AGN

Allergan

$170.26

6.6775 (4.08%)

14:30
01/02/18
01/02
14:30
01/02/18
14:30

Teva announces launch of an authorized generic of Estrace

Teva Pharmaceutical Industries announced the launch of an authorized generic of Estrace Cream in the U.S. Estradiol vaginal cream, USP, 0.01%, is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. This launch is an important addition to Teva's generic women's health portfolio and our growing line of menopause treatments. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva product. Estradiol Vaginal Cream 0.01% had annual sales of approximately $426M in the U.S., according to IMS data as of August 2017.

TEVA

Teva

$19.02

0.07 (0.37%)

AGN

Allergan

$170.26

6.6775 (4.08%)

  • 08

    Jan

  • 16

    Feb

  • 25

    Mar

TEVA Teva
$19.02

0.07 (0.37%)

12/22/17
CANT
12/22/17
NO CHANGE
CANT
Cantor ups price targets for Teva, Valeant, Mylan, Zoetis
Cantor Fitzgerald analyst Louise Chen raised her price target for Neutral-rated Teva (TEVA) to $18 from $10, for Overweight-rated Valeant (VRX) to $25 from $23, for Neutral-Mylan (MYL) to $41 from $34 and for Overweight-rated Zoetis (ZTS) to $85 from $80. Heading into 2018, the analyst believes Perrigo (PRGO) has the best setup in the Specialty Pharmaceuticals space. The company has given the most visibility on its outlook for 2018, Chen tells investors in a research note. She believes Zoetis, Mylan and Horizon Pharma (HZNP) also look good into next year.
12/18/17
UBSW
12/18/17
NO CHANGE
Target $20
UBSW
Neutral
Teva price target raised to $20 from $12 at UBS
UBS analyst Marc Goodman raised his price target on Teva to $20 from $12 driven largely by the larger than expected $3B in cost reductions that improves its operating income and EBITDA. He notes, however, the restructuring will lower revenues, though he has adjusted for that as well. Goodman maintains his Neutral rating on Teva shares.
12/15/17
DBAB
12/15/17
NO CHANGE
Target $20
DBAB
Hold
Teva price target raised to $20 from $14 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert raised his price target for Teva Pharmaceutical to $20 to reflect greater cost reductions under the company's restructuring plan, partially offset by more conservative estimates for generics. The analyst keeps a Hold rating on the shares.
12/15/17
FBCO
12/15/17
UPGRADE
Target $20
FBCO
Neutral
Credit Suisse takes Teva rating to Neutral in third upgrade of day
Credit Suisse analyst Vamil Divan upgraded earlier today Teva Pharmaceutical to Neutral from Underperform and raised his price target for the shares to $20. Following a Goldman Sachs upgrade to Buy and a Morgan Stanley upgrade to Equal Weight, the stock in morning trading is up 7%, or $1.29, to $18.59. The analyst expects investor sentiment to improve as new CEO Kare Schultz executes on his turnaround plan. Divan finds the announced restructuring plan, as well as Schultz's prior track record at Lundbeck, encouraging.
AGN Allergan
$170.26

6.6775 (4.08%)

12/19/17
FBCO
12/19/17
NO CHANGE
Target $214
FBCO
Outperform
Allergan price target lowered to $214 from $224 at Credit Suisse
Credit Suisse analyst Vamil Divan price target lowered to $214 from $224 following the company's disappointing performance during the latter part of 2017. The analyst notes that questions around base business and effect of LOEs have impacted stock, but expectations and valuation are now more reasonable. Divan reiterates an Outperform rating on the shares.
12/08/17
RHCO
12/08/17
NO CHANGE
Target $53
RHCO
Buy
Revance price target raised to $53 from $32 at SunTrust
SunTrust analyst John Boris raised his price target on Revance (RVNC) to $53, saying the company's RT002's clinical data is "de-risked in glabellar lines", offering significant differentiation relative to Allegan's (AGN) Botox. Boris expects GL SAKURA data to be presented in February of 2018, modeling approval by the first half of 2020. The analyst also notes that the RT0002 Phase-2 plantar fasciitis data on track for December and the initiation of Phase 3 cervical dystonia trials for Q2 of next year, keeping his Buy rating on the stock.
12/07/17
12/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yelp (YELP) downgraded to Underweight from Neutral at Piper Jaffray with analyst Sam Kemp saying given the "messiness" of removing Eat24, investors missed that Yelp lowered organic fourth quarter guidance by 2%. 2. Toll Brothers (TOL) downgraded to Outperform from Strong Buy at Raymond James with analyst Buck Horne saying fiscal 2018 gross margins are more cautious than expected due to New York City headwinds ahead of an upcoming supply wave. 3. Priceline (PCLN) and Expedia (EXPE) were downgraded to Neutral from Buy at MKM Partners. 4. Ctrip.com (CTRP) downgraded to Neutral from Overweight at JPMorgan with analyst Alex Yao saying the introduced an opt-in option in early October by removing part of the default purchase setting of bundled products. 5. Allergan (AGN) downgraded to Hold from Buy at Argus analyst David Toung saying the company's Botox may face increasing competition from a botulinum toxin-based product being developed by Revance Therapeutics (RVNC) by 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/17
ARGS
12/07/17
DOWNGRADE
ARGS
Hold
Allergan downgraded to Hold at Argus on growing threats of competition
As noted earlier, Argus analyst David Toung downgraded Allergan (AGN) to Hold from Buy. Toung says the company's Botox may face increasing competition from a botulinum toxin-based product being developed by Revance Therapeutics (RVNC) by 2020. The analyst also notes that Allergan's Restasis dry-eye treatment could be challenged by generics by the middle of next year after a U.S. court ruling invalidated its patent protection.

TODAY'S FREE FLY STORIES

DMPI

DelMar Pharmaceuticals

$0.97

-0.0099 (-1.01%)

06:04
05/22/18
05/22
06:04
05/22/18
06:04
Hot Stocks
DelMar Pharmaceuticals appoints Saiid Zarrabian to full-time CEO »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

VAR

Varian Medical

$118.75

0.3 (0.25%)

06:03
05/22/18
05/22
06:03
05/22/18
06:03
Hot Stocks
Varian notifies Sirtex it will not submit counterproposal to competing bid »

Varian announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSCO

Tractor Supply

$73.63

0.79 (1.08%)

06:03
05/22/18
05/22
06:03
05/22/18
06:03
Recommendations
Tractor Supply analyst commentary  »

Tractor Supply price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

PLAB

Photronics

$8.45

0.5 (6.29%)

06:02
05/22/18
05/22
06:02
05/22/18
06:02
Earnings
Photronics sees Q3 EPS 12c-18c, consensus 9c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

PPBI

Pacific Premier

$42.30

0.35 (0.83%)

06:01
05/22/18
05/22
06:01
05/22/18
06:01
Hot Stocks
Pacific Premier receives stockholder approval for issuance of shares »

Pacific Premier Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TOL

Toll Brothers

$43.60

0.43 (1.00%)

06:01
05/22/18
05/22
06:01
05/22/18
06:01
Hot Stocks
Toll Brothers sees Q3 deliveries between 2,100 and 2,200 units »

Toll Brothers expects FY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

PLAB

Photronics

$8.45

0.5 (6.29%)

06:01
05/22/18
05/22
06:01
05/22/18
06:01
Earnings
Photronics reports Q2 EPS 15c, consensus 7c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

TOL

Toll Brothers

$43.60

0.43 (1.00%)

06:00
05/22/18
05/22
06:00
05/22/18
06:00
Earnings
Toll Brothers sees FY18 revenue $6.64B-$7.31B, consensus $6.97B »

Based on FY 2018's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

GRUB

GrubHub

$103.64

-0.145 (-0.14%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Recommendations
GrubHub analyst commentary  »

GrubHub price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 12

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

05:58
05/22/18
05/22
05:58
05/22/18
05:58
Periodicals
U.S., China reach broad outline on deal to settle ZTE controversy, WSJ reports »

The U.S. and China have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

HURN

Huron

$38.30

0.65 (1.73%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Conference/Events
Huron management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

TOL

Toll Brothers

$43.60

0.43 (1.00%)

05:57
05/22/18
05/22
05:57
05/22/18
05:57
Earnings
Toll Brothers reports Q2 EPS 72c, consensus 76c »

Reports Q2 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

WWE

WWE

$57.86

6.37 (12.37%)

05:56
05/22/18
05/22
05:56
05/22/18
05:56
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WD

Walker & Dunlop

$56.10

1.07 (1.94%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

BUD

AB InBev

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Upgrade
AB InBev rating change  »

AB InBev upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$201.75

2.8 (1.41%)

, BAYRY

Bayer

$0.00

(0.00%)

05:55
05/22/18
05/22
05:55
05/22/18
05:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

MMM

3M

$201.75

2.8 (1.41%)

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$228.74

3.73 (1.66%)

BIIB

Biogen

$277.69

-2.66 (-0.95%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

TEVA

Teva

$21.09

-0.14 (-0.66%)

UTHR

United Therapeutics

$104.12

-2.2 (-2.07%)

VCYT

Veracyte

$6.45

(0.00%)

VRTX

Vertex

$156.15

-1.09 (-0.69%)

NBRV

Nabriva Therapeutics

$4.54

-0.89 (-16.39%)

GILD

Gilead

$67.63

-0.38 (-0.56%)

GSK

GlaxoSmithKline

$40.05

0.005 (0.01%)

HRC

Hill-Rom

$90.70

0.12 (0.13%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

CELG

Celgene

$74.69

-3.7 (-4.72%)

JAZZ

Jazz Pharmaceuticals

$166.01

-1.59 (-0.95%)

ISRG

Intuitive Surgical

$463.18

4.3 (0.94%)

INSM

Insmed

$26.34

-2.16 (-7.58%)

REGN

Regeneron

$296.58

-5.29 (-1.75%)

OCX

OncoCyte

$2.50

-0.05 (-1.96%)

FGEN

FibroGen

$52.55

1.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 20

    Oct

  • 20

    Dec

CCJ

Cameco

$11.38

0.015 (0.13%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Cameco rating change  »

Cameco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$38.17

0.77 (2.06%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Teradyne management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 30

    May

RTN

Raytheon

$213.95

2.88 (1.36%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Downgrade
Raytheon rating change  »

Raytheon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$11.96

-0.41 (-3.31%)

05:54
05/22/18
05/22
05:54
05/22/18
05:54
Conference/Events
Syros Pharmaceuticals management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SPSC

SPS Commerce

$71.88

0.11 (0.15%)

05:53
05/22/18
05/22
05:53
05/22/18
05:53
Conference/Events
SPS Commerce management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 29

    May

  • 12

    Jun

RDCM

Radcom

$19.65

0.25 (1.29%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Conference/Events
Radcom management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 24

    May

  • 29

    May

INFO

IHS Markit

$51.60

0.13 (0.25%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Upgrade
IHS Markit rating change  »

IHS Markit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTM

Quantum

$3.62

-0.06 (-1.63%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.